ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABVC ABVC BioPharma, Inc.

Market Closed 05-01 16:00:00 EDT

1.03

+0.00

0.00%

盘后1.03

+0.000.00%

18:31 EDT

High1.06	Low1.02	Vol18.07K
Open1.05	D1 Closing1.03	Amplitude3.47%
Mkt Cap26.44M	Tradable Cap21.21M	Total Shares25.67M
T/O18.73K	T/O Rate0.09%	Tradable Shares20.60M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ABVC","market":"US","secType":"STK","nameCN":"ABVC BioPharma, Inc.","latestPrice":1.03,"timestamp":1777665600000,"preClose":1.03,"halted":0,"volume":18068,"hourTrading":{"tag":"盘后","latestPrice":1.03,"preClose":1.03,"latestTime":"18:31 EDT","volume":27,"amount":28.209,"timestamp":1777674705216,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0,"floatShares":20595500,"shares":25673225,"eps":-0.393285,"marketStatus":"Market Closed","change":0,"latestTime":"05-01 16:00:00 EDT","open":1.05,"high":1.0557,"low":1.02,"amount":18725.4547704,"amplitude":0.03466,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.393285,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1777881600000},"marketStatusCode":7,"adr":0,"listingDate":1627963200000,"exchange":"NASDAQ","adjPreClose":1.03,"preHourTrading":{"tag":"盘前","latestPrice":1.05,"preClose":1.03,"latestTime":"07:02 EDT","volume":5,"amount":5.25,"timestamp":1777633375804,"change":0.02,"changeRate":0.019417,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":1.03,"preClose":1.03,"latestTime":"18:31 EDT","volume":27,"amount":28.209,"timestamp":1777674705216,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.3098027665418245,"impliedVol":1.8394,"impliedVolPercentile":0.8163},"requestUrl":"/m/hq/s/ABVC/tweets","defaultTab":"tweets","newsList":[{"id":"2632998647","title":"Regencell Bioscience Holdings Faces Investor Lawsuit Alleging Securities Fraud Tied to DOJ Investigation and Stock Volatility","url":"https://stock-news.laohu8.com/highlight/detail?id=2632998647","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632998647?lang=en_us&edition=fundamental","pubTime":"2026-05-02 03:47","pubTimestamp":1777664866,"startTime":"0","endTime":"0","summary":"Regencell (RGC) described itself as an early-stage bioscience company developing traditional Chinese medicine (“TCM”) treatments for ADHD and autis...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/regencell-bioscience-holdings-faces-investor-lawsuit-alleging-securities-fraud-tied-to-doj-investigation-and-stock-volatility?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/regencell-bioscience-holdings-faces-investor-lawsuit-alleging-securities-fraud-tied-to-doj-investigation-and-stock-volatility?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","BK4139","ABVC","RGC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631952919","title":"Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2631952919","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631952919?lang=en_us&edition=fundamental","pubTime":"2026-04-30 04:30","pubTimestamp":1777494600,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., April  29, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/29/3284304/0/en/Neuronetics-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","STIM","BK4082","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626902208","title":"Humanwell Healthcare Subsidiary Gets China Nod for ADHD Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2626902208","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626902208?lang=en_us&edition=fundamental","pubTime":"2026-04-09 16:37","pubTimestamp":1775723836,"startTime":"0","endTime":"0","summary":"China's drug regulator approved the dextromethorphan hydrochloride sustained-release capsules produced by Humanwell Healthcare  subsidiary Yichang Humanwell Pharmaceutical.The approval is for the indication of attention deficit hyperactivity disorder in children aged six years and older, according to a Thursday filing with the Shanghai bourse.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","BK0096","BK4588","ADHD","BK0239","BK0070","BK0188","BK4581","BK0185","LU0128526141.USD","BK4585","BK0028","600079","XLV","LU0029874061.USD","ABVC","HCSG","BK4139","BK4137","BK0012","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622967803","title":"ABVC BioPharma Shareholders Back Board, Equity Plan Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2622967803","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622967803?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:47","pubTimestamp":1774644430,"startTime":"0","endTime":"0","summary":"The latest update is out from ABVC BioPharma ( ($ABVC) ). On March 26, 2026, ABVC BioPharma held its 2026 annual shareholder meeting, where investo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/abvc-biopharma-shareholders-back-board-equity-plan-changes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/abvc-biopharma-shareholders-back-board-equity-plan-changes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4215","BK4139","EQR","BK4585","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622870708","title":"ABVC Biopharma held annual shareholder meeting; quorum reached with 10.6 million shares represented by proxy","url":"https://stock-news.laohu8.com/highlight/detail?id=2622870708","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622870708?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:06","pubTimestamp":1774641992,"startTime":"0","endTime":"0","summary":"ABVC BioPharma held its annual shareholder meeting on March 26, 2026.Shareholders approved the re-election of 11 directors to the board.An increase to the Amended and Restated 2016 Equity Incentive Plan to set the aggregate share reserve at 15% of issued and outstanding common stock as of the meeting date was approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABVC Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 27, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL8VgnJw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622989619","title":"Press Release: LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2622989619","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622989619?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:05","pubTimestamp":1774555500,"startTime":"0","endTime":"0","summary":"Reported positive results from potentially registrational Phase 2 trial of. Advanced LB-102 into late-stage development in multiple indications with initiation of. a pivotal Phase 3 NOVA-2 trial in schizophrenia, and Phase 2 ILLUMINATE-1 trial. Announced pipeline expansion with plans to initiate a Phase 2 trial of LB-102 for the. adjunctive treatment of major depressive disorder  in early 2027. Cash, cash equivalents, and investments of $295.2 million as of December 31, 2025,and proceeds from recent $100 million private placement, expected to provide cash runway into Q2 2029. The Company is building a pipeline that leverages the broad therapeutic potential of LB-102, which has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.-- Reported positive results in January 2025 from a robust 359 patient Phase. 2 trial  of LB-102 in acute schizophrenia. The trial met the. baseline in the Positive and Negative Syndrome Scale  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","BK4233","LBRX","BK4213","BK4007","BK4139","LB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622885239","title":"BrainsWay Completes Additional $6 Million Milestone-Based Investment in Neurolief Ltd. Following FDA Approval of Proliv™Rx System for MDD","url":"https://stock-news.laohu8.com/highlight/detail?id=2622885239","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622885239?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:30","pubTimestamp":1774524600,"startTime":"0","endTime":"0","summary":"BURLINGTON, Mass. and JERUSALEM, March  26, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treat","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/26/3262880/17676/en/BrainsWay-Completes-Additional-6-Million-Milestone-Based-Investment-in-Neurolief-Ltd-Following-FDA-Approval-of-Proliv-Rx-System-for-MDD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4149","BK4585","ABVC","FSS","LU0054578231.USD","BK4588","LABU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620782743","title":"Collegium: Strategic AZSTARYS Acquisition Underpins ADHD Franchise Expansion and Supports Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2620782743","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620782743?lang=en_us&edition=fundamental","pubTime":"2026-03-20 18:16","pubTimestamp":1774001760,"startTime":"0","endTime":"0","summary":"Collegium Pharmaceutical, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Brandon Folkes from H.C. Wainwright ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/collegium-strategic-azstarys-acquisition-underpins-adhd-franchise-expansion-and-supports-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/collegium-strategic-azstarys-acquisition-underpins-adhd-franchise-expansion-and-supports-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVC","ADHD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620247205","title":"Press Release: Collegium to Acquire AZSTARYS(R) from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory","url":"https://stock-news.laohu8.com/highlight/detail?id=2620247205","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620247205?lang=en_us&edition=fundamental","pubTime":"2026-03-19 20:00","pubTimestamp":1773921600,"startTime":"0","endTime":"0","summary":"-- Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio --. -- Enables Greater Impact Across ADHD Patient Communities --. -- AZSTARYS Expected to Generate Over $50 Million in Second Half 2026 Pro Forma Net Revenue --. \"Over the past two years, our team has worked hard to establish AZSTARYS as a leading treatment option for patients with ADHD through innovative patient access solutions and analytically driven execution,\" said Todd Smith, Chief Executive Officer of Corium Therapeutics. \"We are proud of the progress that has been achieved and believe Collegium is well positioned to build on that foundation and continue expanding its reach.\". -- Strategically aligns with Collegium's mission of building a leading,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","ADHD","LENZ","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620846253","title":"Press Release: Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2620846253","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620846253?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:00","pubTimestamp":1773835200,"startTime":"0","endTime":"0","summary":"KANSAS CITY, Kan., March 18, 2026  -- Cingulate Inc. , a biopharmaceutical company utilizing its proprietary Precision Timed Release  drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended December 31, 2025, and provided a corporate update. Highlights include recent U.S. and European patent developments, the closing of a $12 million private investment, and the acceptance of a New Drug Application  for its lead candidate, CTx-1301 .Cingulate received a European patent for CTx-1301 covering the specificity of its tri-modal, precision-timed pulsatile release profile for the treatment of ADHD. The patent , granted on December 17, 2025, extends protection through May 2042 and is expected to be validated in more than 30 European territories, including the United Kingdom.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","CING","ABVC","BK4007","PIPE","BK4585","BK4588","TM","BK4555","BK4139","03160","BK4099","ADHD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616372794","title":"ABVC posts FY 2025 net loss of USD 8.4 million (59% increase)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616372794","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616372794?lang=en_us&edition=fundamental","pubTime":"2026-03-04 06:02","pubTimestamp":1772575364,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABVC Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL2Bg3gf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616941372","title":"Abvc Biopharma Says Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon; Reports Material Weakness In Internal Controls Over Financial Reporting For FY25","url":"https://stock-news.laohu8.com/highlight/detail?id=2616941372","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616941372?lang=en_us&edition=fundamental","pubTime":"2026-03-04 05:54","pubTimestamp":1772574879,"startTime":"0","endTime":"0","summary":"- SEC Filing","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51021667/abvc-biopharma-says-quarterly-period-ended-september-2025-financial-statements-should-not-be-relied","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Abvc Biopharma Says Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon; Reports Material Weakness In Internal Controls Over Financial Reporting For FY25","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616372647","title":"BRIEF-ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon","url":"https://stock-news.laohu8.com/highlight/detail?id=2616372647","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616372647?lang=en_us&edition=fundamental","pubTime":"2026-03-04 05:52","pubTimestamp":1772574761,"startTime":"0","endTime":"0","summary":"BRIEF-ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied UponMarch 3  - ABVC Biopharma Inc ABVC.O:ABVC BIOPHARMA - QTRLY PERIOD ENDED SEPTEMBER, 2025 FINANCIAL STATEMENTS SHOULD NOT BE RELIED UPONABVC BIOPHARMA INC - REPORTS MATERIAL WEAKNESS IN INTERNAL CONTROLS OVER FINANCIAL REPORTING FOR FY2025 - SEC FILINGFurther company coverage: ABVC.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nFWN3ZR0RF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616637269","title":"ABVC Biopharma Inc - Reports Material Weakness in Internal Controls Over Financial Reporting for FY2025 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2616637269","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616637269?lang=en_us&edition=fundamental","pubTime":"2026-03-04 05:50","pubTimestamp":1772574632,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nFWN3ZR0RF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616255563","title":"Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community","url":"https://stock-news.laohu8.com/highlight/detail?id=2616255563","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616255563?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:00","pubTimestamp":1772542800,"startTime":"0","endTime":"0","summary":"– Paris Hilton shares her personal ADHD journey and encourages others to see ADHD in a new light – –Together, Paris and Collegium are reframing common stereotypes and highlighting experiences that are","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/03/3248249/34897/en/Paris-Hilton-Shares-Her-Experience-with-JORNAY-PM-and-Launches-New-Embrace-Your-Sparkle-Campaign-with-Collegium-to-Empower-the-ADHD-Community.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0170899867.USD","EMPW.U","CNS","ABVC","LU0154245673.USD","BK4588","HLT","LU2764262908.HKD","LU0061475181.USD","CII","BK4142","BK4135","LU0823411888.USD","BK4566","BK4139","LU0154245756.USD","LU2764263039.SGD","LU2720916845.USD","LU2764263203.CNY","HCP","ADHD","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614857342","title":"I told my boss I need an ADHD coach and his response was unhelpful. Can we fix our working relationship?","url":"https://stock-news.laohu8.com/highlight/detail?id=2614857342","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614857342?lang=en_us&edition=fundamental","pubTime":"2026-02-27 23:03","pubTimestamp":1772204580,"startTime":"0","endTime":"0","summary":"'I feel like I'm just in shut-down and discouraged mode'. \"I don't know how to deal with a boss who wants me to improve, but gets frustrated if I ask any questions.\" . My background is in partnerships and nonprofits, and I was hired for philanthropy. They thought my skills could transfer, which they can. However, my boss's feedback is always rude and discouraging. It has been challenging. There's so much jargon, and things are constantly happening. Everyone around me said, \"It's going to take you a minute to learn.\" That first year, though, I had many moments with my boss where he seemed impatient with me for not catching on quickly. He told me to ask questions if I didn't know something, but when I did, he would say, \"I feel like we talked about this.\". 'I suggested we get an ADHD coach, and he said we don't have the budget.'. If you're just starting out on your money or career journey and have questions about how to navigate your finances, we want to hear from you. Write to Dollar Si","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADHD","ABVC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614362138","title":"Axsome Explores Solriamfetol In Phase 3 CLARITY Trial For MDD Subset","url":"https://stock-news.laohu8.com/highlight/detail?id=2614362138","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614362138?lang=en_us&edition=fundamental","pubTime":"2026-02-27 17:41","pubTimestamp":1772185272,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics (NasdaqGM: AXSM) has started the CLARITY Phase 3 trial of solriamfetol in major depressive disorder with excessive daytime sleepiness.\nThe trial focuses on a group of MDD patients who experience excessive daytime sleepiness, for which no approved treatments are currently available.\nThis study expands Axsome's clinical program into an area of unmet medical need.\n\nAxsome Therapeutics, listed on the NasdaqGM under the ticker AXSM, develops therapies for central nervous...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/axsome-explores-solriamfetol-in-phase-3-clarity-trial-for-md","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/axsome-explores-solriamfetol-in-phase-3-clarity-trial-for-md","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ABVC","BK4007","AXSM","BK4585","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610681438","title":"Yukiguni Maitake Sets Medium-Term Plan and Outlines FY2026 Q3 Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2610681438","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610681438?lang=en_us&edition=fundamental","pubTime":"2026-02-09 14:59","pubTimestamp":1770620344,"startTime":"0","endTime":"0","summary":"YUKIGUNI MAITAKE CO., LTD. ( ($JP:1375) ) has issued an update. YUKIGUNI MAITAKE CO., LTD. released an outline of its performance review for the th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/yukiguni-maitake-sets-medium-term-plan-and-outlines-fy2026-q3-review?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/yukiguni-maitake-sets-medium-term-plan-and-outlines-fy2026-q3-review?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610689892","title":"Yukiguni Maitake Sees FY Net Y2.01B","url":"https://stock-news.laohu8.com/highlight/detail?id=2610689892","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610689892?lang=en_us&edition=fundamental","pubTime":"2026-02-09 14:31","pubTimestamp":1770618660,"startTime":"0","endTime":"0","summary":"Yukiguni Maitake Co. Ltd. also released the following forecasts:. This content was automatically published based on data and/or text from the original source. For feedback, write to singaporeeditors@dowjones.com.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609807035","title":"ABVC Biopharma Inc. Announces Date for Upcoming Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2609807035","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609807035?lang=en_us&edition=fundamental","pubTime":"2026-02-06 06:30","pubTimestamp":1770330636,"startTime":"0","endTime":"0","summary":"ABVC BioPharma Inc. has announced that it will hold its annual meeting of shareholders virtually on March 9, 2026. During the meeting, shareholders will be asked to consider and vote on the re-election of the current director nominees to serve on the company's Board of Directors until the next annual shareholders meeting and until their successors are duly elected and qualified.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABVC Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL87wwgy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abvcpharma.com","stockEarnings":[{"period":"1week","weight":-0.0374},{"period":"1month","weight":-0.0463},{"period":"3month","weight":-0.4901},{"period":"6month","weight":-0.6321},{"period":"1year","weight":0},{"period":"ytd","weight":-0.5164}],"compareEarnings":[{"period":"1week","weight":0.0094},{"period":"1month","weight":0.0998},{"period":"3month","weight":0.0414},{"period":"6month","weight":0.0566},{"period":"1year","weight":0.2904},{"period":"ytd","weight":0.0568}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.072395},{"month":2,"riseRate":0.125,"avgChangeRate":-0.057705},{"month":3,"riseRate":0.625,"avgChangeRate":0.040736},{"month":4,"riseRate":0.375,"avgChangeRate":0.01167},{"month":5,"riseRate":0.375,"avgChangeRate":-0.010493},{"month":6,"riseRate":0.285714,"avgChangeRate":1.316596},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.097297},{"month":8,"riseRate":0.5,"avgChangeRate":-0.054488},{"month":9,"riseRate":0.375,"avgChangeRate":-0.065685},{"month":10,"riseRate":0.375,"avgChangeRate":-0.067045},{"month":11,"riseRate":0.625,"avgChangeRate":0.051458},{"month":12,"riseRate":0.5,"avgChangeRate":-0.012195}],"exchange":"NASDAQ","name":"ABVC BioPharma, Inc.","nameEN":"ABVC BioPharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ABVC BioPharma, Inc.(ABVC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ABVC BioPharma, Inc.,ABVC,ABVC BioPharma, Inc.股票,ABVC BioPharma, Inc.股票老虎,ABVC BioPharma, Inc.股票老虎国际,ABVC BioPharma, Inc.行情,ABVC BioPharma, Inc.股票行情,ABVC BioPharma, Inc.股价,ABVC BioPharma, Inc.股市,ABVC BioPharma, Inc.股票价格,ABVC BioPharma, Inc.股票交易,ABVC BioPharma, Inc.股票购买,ABVC BioPharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ABVC BioPharma, Inc.(ABVC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction